


Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

Risankizumab Promising for Psoriasis; Plus Canada Approves Brodalumab

The FDA Approved Several New Rheumatology Drugs in 2017
Valeant Prices Psoriasis Treatment at $3,500 Per Month

Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

Brodalumab Approved for Plaque Psoriasis
FDA Approves Valeant’s Drug to Treat Plaque Psoriasis
